Brad earned B.S. (1983), D.V.M. (1986) and M.S. (1986) degrees in six years at the University of Missouri, “enjoyed” an anatomic pathology residency (1986-1989) at the University of Florida, and obtained a Ph.D. (1993) from Duke University while completing postdoctoral training at the Chemical Industry Institute of Toxicology (1989-1993). He was employed by Pathology Associates International as associate director of the Molecular and Immunopathology Division (Frederick, MD; 1993-1994) and later as staff pathologist at the National Center for Toxicological Research (Jefferson, AR; 1994-1996) before moving to Wyeth-Ayerst Research (Plainsboro, NJ; 1996-1997) as a senior scientist. Brad served as an experimental pathologist at Amgen (Thousand Oaks, CA; 1997 to 2004) responsible for evaluating engineered rodents and the efficacy of novel biopharmaceuticals. He subsequently founded an experimental pathology consulting practice (GEMpath, for “Genetically Engineered Mouse Pathology”), working there from 2004 to 2011 in southwestern Utah and later Longmont, CO. Dr. Bolon worked for a time as an associate professor at The Ohio State University College of Veterinary Medicine (Columbus, OH; 2011-2015), after which he returned to Longmont, CO to re-launch GEMpath (2015 to date). Brad is a Diplomate of the American College of Veterinary Pathologists (DACVP, anatomic pathology; 1991) and American Board of Toxicology (DABT; 1996, re-certified 2001, 2006, 2011, 2016) and is a Fellow of the Academy of Toxicological Sciences (FATS; 2011), International Academy of Toxicologic Pathology (FIATP; 2007), and Royal College of Pathologists (FRCPath, 2019). He has written or co-authored over 200 articles and book chapters, has edited or co-edited 5 books, and is a frequent speaker at national and international meetings on toxicologic pathology, especially genetically engineered and induced animal models and toxicologic neuropathology.